NCT04087707View on ClinicalTrials.gov

Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

November 30, 2019

Study Completion Date

November 30, 2019

Conditions
Healthy Volunteer
Interventions
DRUG

Step 1: TS-142

Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

DRUG

Step 2: TS-142

Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days

DRUG

Step 2: Placebo

Elderly participants will receive placebo once daily for 7 consective days

Trial Locations (1)

130-0004

Sumida Hospital, Sumida-ku

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04087707 - Safety, Pharmacokinetic, and Pharmacodynamic Study of TS-142 in Healthy Subjects | Biotech Hunter | Biotech Hunter